Los Angeles, CANCT06641414Now EnrollingIRB Ready

Higher-risk Myelodysplastic Syndrome Clinical Trial in Los Angeles, CA

Access cutting-edge higher-risk myelodysplastic syndrome treatment through this phase 3 clinical trial at a research site in Los Angeles. Study-provided care at no cost to qualified participants.

Sponsored by Ascentage Pharma Group Inc.

Quick Self-Assessment

See if you qualify for this Los Angeles location

Preparing your pre-screening questions…

Expert Care in Los Angeles

Access higher-risk myelodysplastic syndrome specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related higher-risk myelodysplastic syndrome treatment provided free

Apply for This Los Angeles Location

Check if you qualify for this higher-risk myelodysplastic syndrome clinical trial in Los Angeles, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Los Angeles

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Los Angeles site if eligible
  4. 4Begin participation

About This Higher-risk Myelodysplastic Syndrome Study in Los Angeles

A global multicenter, randomized, double-blind, placebo-controlled, pivotal phase III study. To evaluate overall survival (OS) of Lisaftoclax (APG-2575) combined with azacitidine (AZA) vs. placebo combined with azacitidine in newly diagnosed patients with HR-MDS.

Sponsor: Ascentage Pharma Group Inc.

Who Can Participate

Inclusion Criteria

Newly diagnosed higher-risk MDS.
ECOG score of ≤2.
Expected survival ≥ 3 months.
Adequate organ function.
Female subjects of potential childbearing potential have a negative urine or serum pregnancy test before dosing. Subjects of childbearing potential as well as their partners voluntarily use contraception deemed effective by the investigator during the treatment period and for at least six months after the last dose of study drug.
Able to understand and voluntarily sign a written informed consent form, which must be signed prior to the performance of any trial-specified study procedures.
Subjects are able to complete study procedures and follow-up examinations.

Exclusion Criteria

Concomitant other malignancies or prior malignancies with disease-free intervals of less than 1 year at the time of signing the informed consent.
Have undergone hematopoietic stem cell transplantation.
Uncontrolled active infection
Use of moderately potent inducers and moderately potent inhibitors of CYP3A4 within 14 days prior to the first dose of study drug.
MDS or other conditions that cannot be administered enterally.
Any condition that the subject is deemed to be inappropriate to participate in this study after evaluation by the investigator.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Los Angeles?

Yes, this clinical trial (NCT06641414) has an active research site in Los Angeles, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Higher-risk Myelodysplastic Syndrome Treatment Options in Los Angeles, CA

If you're searching for higher-risk myelodysplastic syndrome treatment options in Los Angeles, CA, this clinical trial (NCT06641414) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Los Angeles research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced higher-risk myelodysplastic syndrome specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all higher-risk myelodysplastic syndrome clinical trials near you to find additional studies recruiting in your area.

More Ankylosing Spondylitis Trials in Los Angeles, CA

See all ankylosing spondylitis clinical trials recruiting in Los Angeles — not just this study.

Browse Ankylosing Spondylitis Trials in Los Angeles →

Browse More Trials by Condition

Ankylosing Spondylitis TrialsInterstitial Cystitis TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Los Angeles?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Los Angeles, CA